Seliciclib in malignancies

Bibliography

• Sherr CJ. Cancer cell cycles. Science 1996;274:1672-7
   PubMed Web of Science ®Google Scholar
• Sherr CJ. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res 2000;60:3689-95
   PubMed Web of Science ®Google Scholar
• Morgan DO. Principles of CDK regulation. Nature 1995;374:131-4
   PubMed Web of Science ®Google Scholar
• Grana X, Reddy EP. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 1995;11:211-19
   PubMed Web of Science ®Google Scholar
• Malumbres M, Barbacid M. Mammalian cyclin-dependent kinases. Trends Biochem Sci 2005;30:630-41
   PubMed Web of Science ®Google Scholar
• Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009;9:153-66
   PubMed Web of Science ®Google Scholar
• Sherr CJ. G1 phase progression: cycling on cue. Cell 1994;79:551-5
   PubMed Web of Science ®Google Scholar
• Harper JW, Adams PD. Cyclin-dependent kinases. Chem Rev 2001;101:2511-26
   PubMed Web of Science ®Google Scholar
• Oelgeschlager T. Regulation of RNA polymerase II activity by CTD phosphorylation and cell cycle control. J Cell Physiol 2002;190:160-9
   PubMed Web of Science ®Google Scholar
• An HX, Beckmann MW, Reifenberger G, Gene amplification and overexpression of CDK4 in sporadic breast carcinomas is associated with high tumor cell proliferation. Am J Pathol 1999;154:113-18
   PubMed Web of Science ®Google Scholar
• Mendrzyk F, Radlwimmer B, Joos S, Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma. J Clin Oncol 2005;23:8853-62
   PubMed Web of Science ®Google Scholar
• Yurakh AO, Ramos D, Calabuig-Farinas S, Molecular and immunohistochemical analysis of the prognostic value of cell-cycle regulators in urothelial neoplasms of the bladder. Eur Urol 2006;50:506-15; discussion 515
   PubMed Web of Science ®Google Scholar
• Ortega S, Malumbres M, Barbacid M. Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta 2002;1602:73-87
   PubMed Web of Science ®Google Scholar
• Arnold A, Papanikolaou A. Cyclin D1 in breast cancer pathogenesis. J Clin Oncol 2005;23:4215-24
   PubMed Web of Science ®Google Scholar
• Bergsagel PL, Kuehl WM, Zhan F, Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 2005;106:296-303
   PubMed Web of Science ®Google Scholar
• Senderowicz AM. Novel small molecule cyclin-dependent kinases modulators in human clinical trials. Cancer Biol Ther 2003;2:S84-95
   PubMed Web of Science ®Google Scholar
• Bartkova J, Lukas J, Guldberg P, The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res 1996;56:5475-83
   PubMed Web of Science ®Google Scholar
• Bartkova J, Lukas J, Muller H, Abnormal patterns of D-type cyclin expression and G1 regulation in human head and neck cancer. Cancer Res 1995;55:949-56
   PubMed Web of Science ®Google Scholar
• Aagaard L, Lukas J, Bartkova J, Aberrations of p16Ink4 and retinoblastoma tumour-suppressor genes occur in distinct sub-sets of human cancer cell lines. Int J Cancer 1995;61:115-20
   PubMed Web of Science ®Google Scholar
• Lukas J, Aagaard L, Strauss M, Bartek J. Oncogenic aberrations of p16INK4/CDKN2 and cyclin D1 cooperate to deregulate G1 control. Cancer Res 1995;55:4818-23
   PubMed Web of Science ®Google Scholar
• Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 2001;1:222-31
   PubMed Web of Science ®Google Scholar
• Chen YN, Sharma SK, Ramsey TM, Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc Natl Acad Sci USA 1999;96:4325-9
   PubMed Web of Science ®Google Scholar
• Chen W, Lee J, Cho SY, Fine HA. Proteasome-mediated destruction of the cyclin a/cyclin-dependent kinase 2 complex suppresses tumor cell growth in vitro and in vivo. Cancer Res 2004;64:3949-57
   PubMed Web of Science ®Google Scholar
• Mendoza N, Fong S, Marsters J, Selective cyclin-dependent kinase 2/cyclin A antagonists that differ from ATP site inhibitors block tumor growth. Cancer Res 2003;63:1020-4
   PubMed Web of Science ®Google Scholar
• Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006;24:1770-83
   PubMed Web of Science ®Google Scholar
• O'Connor DS, Wall NR, Porter AC, Altieri DC. A p34(cdc2) survival checkpoint in cancer. Cancer Cell 2002;2:43-54
   PubMed Web of Science ®Google Scholar
• Rieder CL, Maiato H. Stuck in division or passing through: what happens when cells cannot satisfy the spindle assembly checkpoint. Dev Cell 2004;7:637-51
   PubMed Web of Science ®Google Scholar
• Weaver BA, Cleveland DW. Decoding the links between mitosis, cancer, and chemotherapy: the mitotic checkpoint, adaptation, and cell death. Cancer Cell 2005;8:7-12
   PubMed Web of Science ®Google Scholar
• Wesierska-Gadek J, Borza A, Walzi E, Outcome of treatment of human HeLa cervical cancer cells with roscovitine strongly depends on the dosage and cell cycle status prior to the treatment. J Cell Biochem 2009;106:937-55
   Google Scholar
• Yu C, Krystal G, Dent P, Grant S. Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells. Clin Cancer Res 2002;8:2976-84
   PubMed Web of Science ®Google Scholar
• Vesely J, Havlicek L, Strnad M, Inhibition of cyclin-dependent kinases by purine analogues. Eur J Biochem 1994;224:771-86
   PubMedGoogle Scholar
• Legraverend M, Ludwig O, Bisagni E, Synthesis of C2 alkynylated purines, a new family of potent inhibitors of cyclin-dependent kinases. Bioorg Med Chem Lett 1998;8:793-8
   PubMed Web of Science ®Google Scholar
• Legraverend M, Ludwig O, Bisagni E, Synthesis and in vitro evaluation of novel 2,6,9-trisubstituted purines acting as cyclin-dependent kinase inhibitors. Bioorg Med Chem 1999;7:1281-93
   PubMed Web of Science ®Google Scholar
• Wang S, McClue SJ, Ferguson JR, Synthesis and configuration of the cyclin-dependent kinase inhibitor roscovitine and its enantiomer. Tetrahedron Asymmetry 2001;12:2891-4
   Web of Science ®Google Scholar
• Vita M, Abdel-Rehim M, Nilsson C, Stability, pKa and plasma protein binding of roscovitine. J Chromatogr B Analyt Technol Biomed Life Sci 2005;821:75-80
   PubMed Web of Science ®Google Scholar
• Meijer L, Raymond E. Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials. Acc Chem Res 2003;36:417-25
   PubMed Web of Science ®Google Scholar
• Bettayeb K, Oumata N, Echalier A, CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases. Oncogene 2008;27:5797-807
   PubMed Web of Science ®Google Scholar
• Lacrima K, Rinaldi A, Vignati S, Cyclin-dependent kinase inhibitor seliciclib shows in vitro activity in diffuse large B-cell lymphomas. Leuk Lymphoma 2007;48:158-67
   PubMed Web of Science ®Google Scholar
• Ribas J, Boix J, Meijer L. (R)-roscovitine (CYC202, Seliciclib) sensitizes SH-SY5Y neuroblastoma cells to nutlin-3-induced apoptosis. Exp Cell Res 2006;312:2394-400
   PubMed Web of Science ®Google Scholar
• Goh BC, Peh BK, Cui CY, Seliciclib (R-roscovitine) induces apoptosis in undifferentiated nasopharyngeal cancer (NPC) in vivo and in vitro. J Clin Oncol (Meeting Abstracts) 2005;23:3145
   Google Scholar
• McClue SJ, Blake D, Clarke R, In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int J Cancer 2002;102:463-8
   PubMed Web of Science ®Google Scholar
• Meijer L, Borgne A, Mulner O, Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem 1997;243:527-36
   PubMedGoogle Scholar
• MacCallum DE, Melville J, Frame S, Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Res 2005;65:5399-407
   PubMed Web of Science ®Google Scholar
• Raje N, Kumar S, Hideshima T, Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. Blood 2005;106:1042-7
   PubMed Web of Science ®Google Scholar
• Whittaker SR, Walton MI, Garrett MD, Workman P. The cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of cyclin D1, and activates the mitogen-activated protein kinase pathway. Cancer Res 2004;64:262-72
   PubMed Web of Science ®Google Scholar
• Alvi AJ, Austen B, Weston VJ, A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival. Blood 2005;105:4484-91
   PubMed Web of Science ®Google Scholar
• Hahntow IN, Schneller F, Oelsner M, Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells. Leukemia 2004;18:747-55
   PubMed Web of Science ®Google Scholar
• Kim EH, Kim SU, Shin DY, Choi KS. Roscovitine sensitizes glioma cells to TRAIL-mediated apoptosis by downregulation of survivin and XIAP. Oncogene 2004;23:446-56
   PubMed Web of Science ®Google Scholar
• Raynaud FI, Whittaker SR, Fischer PM, In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202. Clin Cancer Res 2005;11:4875-87
   PubMed Web of Science ®Google Scholar
• Weingrill E, Wolfler A, Strunk D, Roscovitine in B-chronic lymphocytic leukemia cells: high apoptosis-inducing efficacy and synergism with alemtuzumab independent of the patients' pretreatment status. Haematologica 2007;92:1286-8
   PubMed Web of Science ®Google Scholar
• Lacrima K, Valentini A, Lambertini C, In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas. Ann Oncol 2005;16:1169-76
   PubMed Web of Science ®Google Scholar
• Galimberti F, Thompson S, Liu X, Targeting the cyclin E-Cdk-2 complex represses lung cancer growth by triggering apoptosis and anaphase catastrophe. Proc Am Assoc Cancer Res 2009:4784
   Google Scholar
• Fleming IN, Hogben M, Frame S, Synergistic inhibition of ErbB signaling by combined treatment with seliciclib and ErbB-targeting agents. Clin Cancer Res 2008;14:4326-35
   PubMed Web of Science ®Google Scholar
• Mgbonyebi OP, Russo J, Russo IH. Roscovitine inhibits the proliferative activity of immortal and neoplastic human breast epithelial cells. Anticancer Res 1998;18:751-5
   PubMed Web of Science ®Google Scholar
• Mgbonyebi OP, Russo J, Russo IH. Roscovitine induces cell death and morphological changes indicative of apoptosis in MDA-MB-231 breast cancer cells. Cancer Res 1999;59:1903-10
   PubMed Web of Science ®Google Scholar
• Ortiz-Ferron G, Yerbes R, Eramo A, Roscovitine sensitizes breast cancer cells to TRAIL-induced apoptosis through a pleiotropic mechanism. Cell Res 2008;18:664-76
   PubMed Web of Science ®Google Scholar
• Appleyard MV, O'Neill MA, Murray KE, Seliciclib (CYC202, R-roscovitine) enhances the antitumor effect of doxorubicin in vivo in a breast cancer xenograft model. Int J Cancer 2009;124:465-72
   PubMed Web of Science ®Google Scholar
• Wesierska-Gadek J, Wandl S, Kramer MP, Roscovitine up-regulates p53 protein and induces apoptosis in human HeLaS(3) cervix carcinoma cells. J Cell Biochem 2008;105:1161-71
   PubMed Web of Science ®Google Scholar
• Coley HM, Shotton CF, Kokkinos MI, Thomas H. The effects of the CDK inhibitor seliciclib alone or in combination with cisplatin in human uterine sarcoma cell lines. Gynecol Oncol 2007;105:462-9
   PubMed Web of Science ®Google Scholar
• de la Motte S, Gianella-Borradori A. Pharmacokinetic model of R-roscovitine and its metabolite in healthy male subjects. Int J Clin Pharmacol Ther 2004;42:232-9
   PubMed Web of Science ®Google Scholar
• Benson C, White J, De Bono J, A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer 2007;96:29-37
   PubMed Web of Science ®Google Scholar
• Hsieh WS, Soo R, Peh BK, Pharmacodynamic effects of seliciclib, an orally administered cell cycle modulator, in undifferentiated nasopharyngeal cancer. Clin Cancer Res 2009;15:1435-42
   PubMed Web of Science ®Google Scholar
• Nutley BP, Raynaud FI, Wilson SC, Metabolism and pharmacokinetics of the cyclin-dependent kinase inhibitor R-roscovitine in the mouse. Mol Cancer Ther 2005;4:125-39
   PubMed Web of Science ®Google Scholar
• Vita M, Abdel-Rehim M, Olofsson S, Tissue distribution, pharmacokinetics and identification of roscovitine metabolites in rat. Eur J Pharm Sci 2005;25:91-103
   PubMed Web of Science ®Google Scholar
• Pierga J-Y, Faivre S, Vera K, A phase I and pharmacokinetic (PK) trial of CYC202, a novel oral cyclin-dependent kinase (CDK) inhibitor, in patients (pts) with advanced solid tumors. Proc Am Soc Clin Oncol 2003;22:840
   Google Scholar
• Jackson RC, Barnett AL, McClue SJ, Green SR. Seliciclib, a cell-cycle modulator that acts through the inhibition of cyclin-dependent kinases. Expert Opin Drug Discov 2008;3:131-43
   PubMed Web of Science ®Google Scholar
• Available from: http://www.cyclacel.com/cyc/rd/programs/oncology/seliciclib/seliciclib.pdf
   Google Scholar
• Siegel-Lakhai WS, Rodenstein DO, Beijnen JH, Phase I study of seliciclib (CYC202 or R-roscovitine) in combination with gemcitabine (gem)/cisplatin (cis) in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts) 2005;23:2060
   Google Scholar
• Available from: http://clinicaltrials.gov/show/NCT00372073
   Google Scholar
• Yeo W, Goh B, Le Tourneau C, A phase II randomized study of oral seliciclib in patients with previously treated nasopharyngeal carcinoma. J Clin Oncol (Meeting Abstracts) 2009;27:6026
   Google Scholar
• Yu Q, Geng Y, Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature 2001;411:1017-21
   PubMed Web of Science ®Google Scholar
• Grant S, Roberts JD. The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy. Drug Resist Updat 2003;6:15-26
   PubMed Web of Science ®Google Scholar
• Shah MA, Schwartz GK. Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin Cancer Res 2001;7:2168-81
   PubMed Web of Science ®Google Scholar
• Motwani M, Delohery TM, Schwartz GK. Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. Clin Cancer Res 1999;5:1876-83
   PubMed Web of Science ®Google Scholar
• Wang S, Guo CY, Castillo A, Effect of bryostatin 1 on taxol-induced apoptosis and cytotoxicity in human leukemia cells (U937). Biochem Pharmacol 1998;56:635-44
   PubMed Web of Science ®Google Scholar
• Wang S, Wang Z, Boise LH, Bryostatin 1 enhances paclitaxel-induced mitochondrial dysfunction and apoptosis in human leukemia cells (U937) ectopically expressing Bcl-xL. Leukemia 1999;13:1564-73
   PubMed Web of Science ®Google Scholar